Glumetza, a once-daily extended-release formulation of metformin hydrochloride, was granted FDA approval in June 2005 for the treatment of type 2 diabetes.
According to Biovail, the drug’s manufacturer, Glumetza “may offer potential advantages such as less frequent dosing and proven effectiveness in combination with other diabetes drugs.” In addition, they say that Glumetza offers “excellent tolerability that allows physicians to more quickly administer a high enough dose to provide [blood glucose] control without significantly increasing the incidence of nausea, diarrhea and other side effects that are sometimes caused by metformin products.”
Glumetza is not recommend for people with kidney problems, heart failure that is treated with medicine, or diabetic ketoacidosis. The most common side effects of Glumetza include diarrhea, nausea and upset stomach. Glumetza can also cause lactic acidosis.
Source: Biovail Corp.